Aged, 80 and over
"Aged, 80 and over" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A person 80 years of age and older.
Descriptor ID |
D000369
|
MeSH Number(s) |
M01.060.116.100.080
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aged, 80 and over".
Below are MeSH descriptors whose meaning is more specific than "Aged, 80 and over".
This graph shows the total number of publications written about "Aged, 80 and over" by people in this website by year, and whether "Aged, 80 and over" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 35 | 35 | 1995 | 0 | 32 | 32 | 1996 | 0 | 26 | 26 | 1997 | 0 | 37 | 37 | 1998 | 0 | 45 | 45 | 1999 | 0 | 46 | 46 | 2000 | 0 | 55 | 55 | 2001 | 0 | 47 | 47 | 2002 | 0 | 36 | 36 | 2003 | 1 | 86 | 87 | 2004 | 0 | 86 | 86 | 2005 | 0 | 130 | 130 | 2006 | 0 | 157 | 157 | 2007 | 1 | 165 | 166 | 2008 | 0 | 164 | 164 | 2009 | 0 | 186 | 186 | 2010 | 1 | 220 | 221 | 2011 | 0 | 236 | 236 | 2012 | 0 | 228 | 228 | 2013 | 1 | 253 | 254 | 2014 | 0 | 242 | 242 | 2015 | 2 | 302 | 304 | 2016 | 0 | 314 | 314 | 2017 | 0 | 319 | 319 | 2018 | 0 | 329 | 329 | 2019 | 0 | 342 | 342 | 2020 | 0 | 271 | 271 | 2021 | 0 | 214 | 214 | 2022 | 0 | 45 | 45 | 2023 | 0 | 36 | 36 | 2024 | 0 | 16 | 16 |
To return to the timeline, click here.
Below are the most recent publications written about "Aged, 80 and over" by people in Profiles.
-
Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, Kubicki T, Jakubowiak AJ. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 Oct 07; 14(1):170.
-
Panian J, Saidian A, Hakimi K, Ajmera A, Anderson WJ, Barata P, Berg S, Signoretti S, Lee Chang S, D'Andrea V, George D, Dzimitrowicz H, El Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus GP, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay RR. Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. Oncologist. 2024 Oct 03; 29(10):870-877.
-
French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res. 2024 Sep 03; 30(17):3757-3767.
-
Miller E, Biesemier A, Coomes DM, Raghavan SS. PRAME Expression in Merkel Cell Carcinoma. Am J Surg Pathol. 2024 Oct 01; 48(10):1270-1276.
-
Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez J, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain JM, Ruiz M, Brammer JE, Prakash R, Iyer SP, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos B, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Brooks TR, Jagadeesh D, Hariharan N, Goodman AM, Hartman G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood Adv. 2024 Jul 09; 8(13):3507-3518.
-
Westrick AC, Kobayashi LC, Kirch M, Singer D, Malani PN, Kullgren JT, Solway E, Finlay JM. The Joys and Stresses of Social Relationships and the Effect on Resiliency During the COVID-19 Pandemic: A National Survey of U.S. Older Adults. Gerontologist. 2024 07 01; 64(7).
-
Borgers JSW, van Wesemael TJ, Gelderman KA, Rispens T, Verdegaal EME, Moes DJAR, Korse CM, Kapiteijn E, Welters MJP, van der Burg SH, van Houdt WJ, van Thienen JV, Haanen JBAG, van der Woude D. Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. J Immunother Cancer. 2024 Jun 30; 12(6).
-
Wan S, Powers JD, Kutner JS, Fischer SM, Knoepke CE, Portz JD. Association Between Patient Portal Activities and End-of-Life Outcomes Among Deceased Patients in the Last 12 Months of Life. J Palliat Med. 2024 Jul; 27(7):916-921.
-
Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, Pollyea DA. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. 2024 06 01; 109(6):1766-1778.
-
Shivakumar N, King AA, Lyons KD, L'Hotta AJ. "If I have a limited amount of time left, this is not how I want to spend it": A qualitative descriptive study of factors influencing daily life participation following a cancer diagnosis. Psychooncology. 2024 Jun; 33(6):e6366.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|